共 13 条
- [1] LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIALHAEMATOLOGICA, 2017, 102 : 618 - 619Wang, Y.Chang, Y. -J.Huang, X. -J.
- [2] G-CSF primed bone marrow in HLA-haploidentical transplantation using post-transplantation cyclophosphamide (PTCY) could promote tolerance and further reduce risk of GVHDBONE MARROW TRANSPLANTATION, 2019, 54 : 571 - 572Durakovic, NadiraPeric, ZinaidaDesnica, LanaServenti-Seiwerth, RankaMikulic, MirtaMelamed, BrianOstojic, AlenPulanic, DrazenRoncevic, PavleGrubic, ZoranaVrhovac, Radovan
- [3] Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)Science China(Life Sciences) , 2020, (04) : 571 - 581Feifei TangYajing XuHuiren ChenLanping XuXiaohui ZhangYu WangQifa LiuDepei WuXiaojun Huang
- [4] Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)SCIENCE CHINA-LIFE SCIENCES, 2020, 63 (04) : 571 - 581Tang, FeifeiXu, YajingChen, HuirenXu, LanpingZhang, XiaohuiWang, YuLiu, QifaWu, DepeiHuang, Xiaojun
- [5] Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)Science China Life Sciences, 2020, 63 : 571 - 581Feifei TangYajing XuHuiren ChenLanping XuXiaohui ZhangYu WangQifa LiuDepei WuXiaojun Huang
- [6] Ancestim (SCF) and high-dose twice-daily filgrastim (G-CSF) is superior to G-CSF alone or cyclophosphamide plus G-CSF for mobilization of peripheral blood stem cells (PBSC) in patients with indolent lymphoproliferative disorders previously treated with fludarabine; Results of a historically-controlled Phase-II study.BLOOD, 2006, 108 (11) : 873A - 873ASeymour, John FrancisMorgan, SuePrince, MilesWesterman, David AlanWolf, Max M.Carney, Dennis A.Yuen, Kally
- [7] A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: A trial of the Japan Clinical Oncology GroupJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (05) : 325 - 330Takashima, SSaeki, TAdachi, IWatanabe, TSasaki, YMurai, HTabei, TOgita, MSano, MKanda, KShimoyama, M
- [8] DOWNREGULATION OF L-SELECTIN EXPRESSION ON DONOR CD4+ T CELLS USING G-CSF CORRELATES WITH A LOWER INCIDENCE OF GRADES II-IV ACUTE GVHD IN PATIENTS AFTER HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND MARROW TRANSPLANTATIONHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 329 - 329Chang, Ch.Zhao, X. -Y.Huo, M. -R.Huang, X. -J.
- [9] First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity ConditioningBLOOD, 2017, 130Bethge, WolfgangMielke, StephanNiederwieser, DietgerMeisel, RolandBunjes, Donald W.Brecht, ArneKuball, JurgenKaritzky, SandraHoltkamp, SilkeSiewert, ChristianePflitsch, StefanieSchumm, MichaelEyrich, Matthias K.Vucinic, VladanWiesneth, MarkusWestinga, KasperHandgretinger, Rupert
- [10] Treatment of relapse of AML and MDS after allogeneic stem cell transplantation using low-dose chemotherapy, donor PBSC and GMCSF: Final results from a prospective, multicenter phase II trial by the German cooperative transplant groupBLOOD, 2007, 110 (11) : 492A - 492ASchmid, ChristophTischer, JohannaSteljes, MatthiasSchleuning, MichaelSchwerdtfeger, RainerHegenbart, UteSchubert, JoergVogel, WichardGruhn, BerdLallinger, ChristianeLedderose, GeorgBornhaeuser, MartinKienast, JoachimKolb, Hans-Jochem